Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather busy. We plan to hang with all of our short people — one of whom has made a surprise appearance — and, otherwise, catch up on life. If possible, a nap may occur. And what about you? Is it time for your summer getaway, yet? If not, now is a good time to make plans. Regardless, you can still enjoy the great outdoors — beaches, lakes and mountains are beckoning — or a lovely night out with someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Amgen (AMGN) is facing barriers from insurers as it tries to get patients on its new $575-a-month migraine drug before competition emerges in September, Reuters reports. Large insurers set requirements for patients to document how they suffer from a defined number of headaches each month and show they have tried older drugs first. Others have made it even harder by covering prescriptions from — or in consultation with — a neurologist, and specifically a member of the United Council for Neurologic Subspecialties, but only 3 percent of U.S. neurologists are certified.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!